Business Description
![Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd logo](https://static.gurufocus.com/logos/0C00000CM5.png?14)
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : IL0006290147
Compare
Compare
Traded in other countries / regions
TEVA.USATEVA.Israel0LER.UKTEV.GermanyTEVA.MexicoT1EV34.BrazilTEVA.Austria IPO Date
1961-01-01Description
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 2.74 | |||||
Debt-to-EBITDA | 15.26 | |||||
Interest Coverage | 3.26 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.22 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.4 | |||||
3-Year EPS without NRI Growth Rate | -0.1 | |||||
3-Year FCF Growth Rate | 8.9 | |||||
3-Year Book Growth Rate | -9.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.05 | |||||
Future 3-5Y Total Revenue Growth Rate | 1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.19 | |||||
9-Day RSI | 37.96 | |||||
14-Day RSI | 48.18 | |||||
6-1 Month Momentum % | 60.94 | |||||
12-1 Month Momentum % | 119.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.89 | |||||
Quick Ratio | 0.61 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 180.92 | |||||
Days Sales Outstanding | 78.57 | |||||
Days Payable | 109.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | 7.06 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.95 | |||||
Operating Margin % | 20.79 | |||||
Net Margin % | -3.08 | |||||
FCF Margin % | 5.49 | |||||
ROE % | -6.73 | |||||
ROA % | -1.15 | |||||
ROIC % | 8.37 | |||||
ROC (Joel Greenblatt) % | 3.05 | |||||
ROCE % | 0.6 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 5.43 | |||||
PE Ratio without NRI | 6.17 | |||||
PS Ratio | 1.15 | |||||
PB Ratio | 2.53 | |||||
Price-to-Free-Cash-Flow | 20.71 | |||||
Price-to-Operating-Cash-Flow | 13.09 | |||||
EV-to-EBIT | 191.47 | |||||
EV-to-Forward-EBIT | 42.02 | |||||
EV-to-EBITDA | 27.25 | |||||
EV-to-Forward-EBITDA | 18.74 | |||||
EV-to-Revenue | 2.23 | |||||
EV-to-Forward-Revenue | 2.24 | |||||
EV-to-FCF | 40.44 | |||||
Price-to-Projected-FCF | 1.43 | |||||
Price-to-Median-PS-Value | 1.51 | |||||
Earnings Yield (Greenblatt) % | 0.52 | |||||
FCF Yield % | 4.7 | |||||
Forward Rate of Return (Yacktman) % | 15.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Teva Pharmaceutical Industries Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₪) | 60,089.024 | ||
EPS (TTM) (₪) | -1.54 | ||
Beta | 0 | ||
Volatility % | 28.76 | ||
14-Day RSI | 48.18 | ||
14-Day ATR (₪) | 1.281226 | ||
20-Day SMA (₪) | 62.6765 | ||
12-1 Month Momentum % | 119.68 | ||
52-Week Range (₪) | 27.84 - 64.94 | ||
Shares Outstanding (Mil) | 1,132.64 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Teva Pharmaceutical Industries Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Teva Pharmaceutical Industries Ltd Stock Events
Event | Date | Price(₪) | ||
---|---|---|---|---|
No Event Data |
Teva Pharmaceutical Industries Ltd Frequently Asked Questions
What is Teva Pharmaceutical Industries Ltd(XTAE:TEVA)'s stock price today?
The current price of XTAE:TEVA is ₪61.20. The 52 week high of XTAE:TEVA is ₪64.94 and 52 week low is ₪27.84.
When is next earnings date of Teva Pharmaceutical Industries Ltd(XTAE:TEVA)?
The next earnings date of Teva Pharmaceutical Industries Ltd(XTAE:TEVA) is 2024-08-02 Est..
Does Teva Pharmaceutical Industries Ltd(XTAE:TEVA) pay dividends? If so, how much?
Teva Pharmaceutical Industries Ltd(XTAE:TEVA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |